Our Top 5 Most Viewed Conference Video Interviews of 2024
Applied Clinical Trials sat down on-site with many KOLs at some of industry's largest gatherings in 2024 including SCOPE, DIA, and DPHARM.
Below is a list of the most viewed video interviews from Applied Clinical Trials' on-site conference coverage in 2024.
1. DIA 2024: Ginny Beakes-Read of Johnson & Johnson Discusses Regulatory Challenges
In an interview at DIA 2024, Beakes-Read, head, global regulatory policy and intelligence, Johnson & Johnson Innovative Medicine highlights the integration of technological advancements into drug development and benefits patients are seeing from FDA's Accelerated Approval Program.
Watch the interview here.
2. DPHARM 2024: Acclinate CEO Del Smith Highlights the Roles of Technology and Engagement in Clinical Research
In an interview at DPHARM 2024, Smith discusses how predictive modeling and community engagement can increase diversity.
Watch the interview here.
3. SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
In an interview at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.
Watch the interview here.
4. SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials
In an interview at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.
Watch the interview here.
5. DIA 2024: Rob DiCicco of TransCelerate Biopharma Discusses the State of AI in Clinical Research
In an interview at DIA 2024, DiCicco, vice president, portfolio management, TransCelerate Biopharma highlights the use of artificial intelligence in clinical research from the perspectives of different stakeholders.
Watch the interview here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
